Information Provided By: 
Fly News Breaks for March 17, 2016
CERS
Mar 17, 2016 | 07:53 EDT
Stephens analyst Drew Jones said Cerus receiving an extended label claim from the FDA further opens up a significant portion of the U.S. platelet market for the company's Intercept system. Some customers who have contracts signed with Cerus were awaiting this approval prior to implementing Intercept, Jones added. The analyst, who continues to think U.S. platelet revenue will begin to ramp in 2017, and possibly as early as the second half of this year, reiterates his Overweight rating and $9 price target on Cerus shares.
News For CERS From the Last 2 Days
There are no results for your query CERS
